Psychiatry · Medical Literature
Accelerated, Neuronavigated Neuromodulation for Negative Symptoms in Schizophrenia: Protocol for a Randomized Controlled Pilot Trial.
Abstract
Background Negative symptoms (NS) of schizophrenia, including avolition, anergia, and social withdrawal cause major functional impairment and have limited treatment options. Repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex (LDLPFC) shows promise in alleviating NS, though response remains modest, and multi-week protocols are often burdensome. A five-day, high-dose intermittent theta burst stimulation (iTBS) protocol using fMRI-guided neuronavigation has demonstrated rapid and sustained effects in major depression. Given the overlap between depressive lassitude and NS domains, accelerated neuronavigated iTBS may hold promise in schizophrenia with NS. Methods This multisite, randomized, patient- and rater-blinded trial evaluates the feasibility, safety, and preliminary efficacy of such a protocol in individuals with schizophrenia spectrum disorders. Seventy-five adults with clinically significant NS will receive either: (1) neuronavigated active iTBS targeting LDLPFC regions most anti-correlated with the subgenual anterior cingulate cortex (sgACC) (2) non-neuronavigated active iTBS using scalp-based coordinates; or (3) neuronavigated sham stimulation over 10 daily sessions spanning 5 consecutive days (90,000 pulses total), with follow-ups at 1 week, 1 month, and 3 months. Résultats Outcomes include a reduction in NS; Efficacy comparisons between neuronavigation and non-neuronavigation; Feasibility and safety; Change in social and affective information processing; Change in depressive symptoms. Conclusion Results will inform future trials, while comparison of targeting strategies will clarify the utility of neuronavigation. If successful, this trial will offer a time-efficient, personalized intervention for NS.
Clinical relevance
In adults with clinically significant negative symptoms of schizophrenia spectrum disorders, is a five-day, high-dose accelerated intermittent theta burst stimulation (iTBS) protocol using fMRI-guided neuronavigation to target the left dorsolateral prefrontal cortex feasible, safe, and potentially efficacious compared to non-neuronavigated active iTBS and neuronavigated sham iTBS? __SNAPSHOT__ {"studyDesign":"Randomized controlled pilot trial (protocol paper); multisite, three-arm, patient- and rater-blinded","setting":"Multisite; country not reported in the provided abstract","sampleSize":"Planned n=75 (three arms of approximately 25 each; exact allocation ratio not reported in the provided abstract)","population":"Adults with schizophrenia spectrum disorders and clinically significant negative symptoms; specific diagnostic thresholds, severity cutoffs, age range, and exclusion criteria not fully reported in the provided abstract","intervention":"Arm 1: Neuronavigated active iTBS targeting LDLPFC regions most anti-correlated with the subgenual anterior cingulate cortex (sgACC), delivered as an accelerated five-day, high-dose protocol (10 sessions/day per available trial registration data); Arm 2: Non-neuronavigated active iTBS using scalp-based coordinates (BEAM-F3), same accelerated schedule","comparator":"Arm 3: Neuronavigated sham iTBS using identical session structure and procedures as active treatment","primaryOutcome":"Feasibility and safety (primary); preliminary efficacy on negative symptoms (secondary); specific rating scale and minimal clinically important difference threshold not reported in the provided abstract","followUp":"Not reported in the provided abstract","fundingSource":"Not reported in the provided abstract"}
Key findings
This is a protocol paper for an ongoing pilot RCT. No efficacy, safety, or feasibility outcome data are reported. The abstract describes study design and rationale only. No primary or secondary outcome results, effect sizes, confidence intervals, p-values, adverse event frequencies, or NNT/NNH values are available. All findings are pending trial completion.
Practice implications
This paper establishes only a trial protocol — it does not establish clinical efficacy, safety, or feasibility of accelerated neuronavigated iTBS for negative symptoms in schizophrenia. The study is motivated by two converging rationales: (1) existing evidence that rTMS/iTBS targeting the LDLPFC produces modest improvements in negative symptoms, and (2) the demonstrated rapid antidepressant efficacy of accelerated, fMRI-guided neuronavigated iTBS in major depression, with the hypothesis that overlapping neurobiological mechanisms may translate to the negative symptom domain. The three-arm design is methodologically sound in that it simultaneously tests both the therapeutic technology (accelerated iTBS) and the precision-targeting strategy (neuronavigation vs. scalp coordinates), which addresses a key pragmatic question. However, no conclusions about patient benefit, responder characteristics, or practice change can be drawn at this stage. The pilot sample size (n=75) is appropriate for feasibility and signal detection but will be substantially underpowered for definitive efficacy conclusions. Clinicians should note that the abstract was truncated and complete methodological details — including primary outcome scale, severity thresholds, follow-up duration, and exclusion criteria — were not available for review. Only the abstract was available; this is a critical limitation of this summary. __LIMITATIONS__ Protocol/design paper only — no outcome data are available; all efficacy and safety conclusions are premature.,Abstract provided is truncated; complete methods including primary outcome measure, full inclusion/exclusion criteria, follow-up duration, and statistical analysis plan were not reviewable.,Pilot sample size (n=75, ~25 per arm) is insufficient for definitive efficacy conclusions and will be underpowered to detect modest effect sizes with adequate precision.,Patient- and rater-blinding but not investigator-blinding is described; the robustness of blinding in an accelerated iTBS paradigm (somatic sensations, scalp discomfort) is a known challenge and not yet validated in this protocol.,Extrapolation of the sgACC anti-correlation targeting strategy from major depression to schizophrenia is a hypothesis, not an established principle; negative symptoms and depressive lassitude share phenomenological overlap but may differ in circuitry.,Multisite design introduces potential inter-site variability in neuronavigation quality, stimulation delivery, and rater calibration.,Generalizability is unknown until enrollment characteristics (age, sex, illness duration, antipsychotic regimen, comorbidities) are reported.,Funding source not reported; potential conflicts of interest cannot be assessed.,The accelerated schedule (10 sessions/day over 5 days per trial registration) has been validated in depression but inter-session interval effects and tolerability in schizophrenia — a population with potential increased seizure susceptibility and cognitive vulnerability — require prospective safety documentation. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ This is a published protocol for an ongoing three-arm pilot RCT evaluating whether a five-day, high-dose, fMRI-neuronavigated accelerated iTBS regimen is feasible and potentially efficacious for negative symptoms in schizophrenia spectrum disorders; no outcome data are yet available. The design is scientifically well-motivated and addresses an important gap — whether precision targeting via sgACC anti-correlation improves upon standard scalp-coordinate iTBS — but no practice implications can be drawn until trial results are reported. Clinicians should monitor this trial for completion; accelerated iTBS for negative symptoms remains investigational and is not yet ready for routine clinical application.